Inactive Instrument

Insiders Qiagen Nasdaq

Equities

NL0012169213

Insiders

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Qiagen N.V. Appoints Eva Pisa as New Supervisory Board Member	22-06-23	CI
QIAGEN Appoints Thomas Ebeling as a Member of the Supervisory Board	21-02-22	CI
QIAGEN Announces Dr. Toralf Haag Has Been Appointed as A Member of the Supervisory Board	21-01-08	CI
QIAGEN N.V. Announces Appointment of Jean-Pascal Viola, Senior Vice President, Head of the Molecular Diagnostics Business Area	20-10-27	CI
QIAGEN N.V. Announces Chairman and Supervisory Board Changes	20-08-21	CI
Qiagen chairman quits after Thermo Fisher's takeover bid fails	20-08-21	RE
Qiagen Appoints Thierry Bernard as CEO	20-03-31	CI
Illumina : Qiagen CEO quits amid genetic sequencing U-turn, shares tumble	19-10-08	RE
QIAGEN Announces Executive Changes	19-10-07	CI
QIAGEN N.V. Appoints Dr. Barthold Piening as the New Senior Vice President, Head of Global Operations and Member of the Executive Committee, Effective December 1, 2018	19-02-03	CI
Qiagen Announces Executive Changes	15-05-05	CI
Qiagen NV Announces Board Changes	14-05-06	CI
Qiagen Proposes Changes to Members of Supervisory Board	13-04-29	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

Qiagen: In line Q4; routine business prospects remain intact

QIAGEN : In line Q4; routine business prospects remain intact

February 07, 2024 at 10:30 am EST

+39.41% on our US portfolio vs. 25.67% on the S&P 500 net Total Return

Replicate our performance

fermer